๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin

โœ Scribed by Nishio, K; Sugimoto, Y; Nakagawa, K; Niimi, S; Fujiwara, Y; Bungo, M; Kasahara, K; Fujiki, H; Saijo, N

Book ID
109836447
Publisher
Nature Publishing Group
Year
1990
Tongue
English
Weight
931 KB
Volume
62
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Mechanism of cross-resistance to cisplat
Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line
โœ Shivendra V. Singh; Bing H. Xu; Jitesh P. Jani; Erling O. Emerson; Mary G. Backe ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 730 KB

This study was undertaken to elucidate the mechanism@) of cross-resistance to cisplatin (CDDP) in a mitomycin C (MMC)resistant human bladder cancer cell line, J82/MMC. The J82/ MMC cell line displayed 2-to 3-fold cross-resistance to CDDP and carboplatin when compared to the parental )82/WT cells. Dr

Modulation of induced resistance to adri
Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate
โœ Brenda J. Foster; Karen R. Grotzinger; Wilma M. McKoy; Lawrence V. Rubinstein; T ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer ๐ŸŒ English โš– 602 KB

The clinical utility of adriamycin in the treatment of patients with metastatic breast cancer is often-limited by the development of drug resistance. It has been recognized that in addition to the development of primary resistance against adriamycin, malignant cells can simultaneously develop cross-